LOOP DIURETIC TORASEMID IN THE TREATMENT OF ARTERIAL HYPERTENSION
- Autores: GORDEEV I.G.1, TARATUKHIN Y.O.1, BAIKOVA O.A.1
-
Afiliações:
- N.I. Pirogov Russian National Research Medical University
- Edição: Nº 2 (2016)
- Páginas: 59-64
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277350
- ID: 277350
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article focuses on torasemide as a drug of choice for arterial hypertension management. Diuretics are a first line group in pharmacotherapy of this pathology, however the group is highly geterogenic. Preference for torasemide is based upon its pharmacokinetic specifics and blockage of aldosterone effects, that it leads to pleiotropic positive effects. Evidence data is considered for torasemide prescription in arterial hypertension, as the aspects of its effect in cardiovascular comorbidities.
Palavras-chave
Texto integral
Sobre autores
Ivan GORDEEV
N.I. Pirogov Russian National Research Medical University
Email: cardio-15@yandex.ru
MD, Professor, Head of the Department of Hospital Therapy № 1, Medical Faculty 117997, Moscow, 1 Ostrovityanova St
Yevgeniy TARATUKHIN
N.I. Pirogov Russian National Research Medical UniversityPhD, Department of Hospital Therapy № 1, Medical Faculty 117997, Moscow, 1 Ostrovityanova St
Oksana BAIKOVA
N.I. Pirogov Russian National Research Medical UniversityMD, Professor, Department of Hospital Therapy № 1, Medical Faculty 117997, Moscow, 1 Ostrovityanova St
Bibliografia
- Глобальные цели ВОЗ по неинфекционным заболеваниям к 2025 году (Global Voluntarily Goals for non-communicable diseases 2025 (URL: http://www.who.int/nmh/ncd-tools/definition-targets/en/)
- Libby P., Bonow R.O., Mann D.L. et al. Braunwald's Heart Disease (8th ed.). Elsevier, 2008. 2274 p.
- Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б., Белявская Д.В., Выдрина О.И., Пастернак Е.Ю., Белоусов Д.Ю. и группа исследователей. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV: приверженность врачей. Российский кардиологический журнал. 2015;1(1 17):59-66
- Фомин В.В. Антиальдостероновое действие торасемида: случайность или необходимость? РМЖ. 2012;14:693
- Теплова Н.В., Таратухин Е.О. Злокачественная артериальная гипертензия. Palmarium Acad Publish, 2014. 300 с
- Kumar N., Calhoun D.A., Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr. Blood Press. Control. 2013;6:139-51.
- Tamargo J., Segura J., Ruilope L.M. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Exp. Opin. in Pharmacotherapy. 2014;15(5):605-21.
- Roush G.C., Kaur R., Ernst M.E. Diuretics: a review and update. J. of Cardiovasc. Pharm. and Therapeutics. 2014;19(1 ):5-13.
- Adam O., Zimmer C., Hanke N., Hartmann R.W., Klemmer B., Böhm M., Laufs U. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice. J. Mol. Cell Cardiol. 2015;85:140-50.
- Mentz R.J., Hasselblad V., DeVore A.D., Metra M., Voors A.A., Armstrong P.W., Ezekowitz J.A., Tang W.H., Schulte P.J., Anstrom K.J., Hernandez A.F., Velasquez E.J., O'Connor C.M. Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF Trial). Am J. Cardiol. 2016;117(3):404-1 1.
- Haider D.G., Lindner G., Wolzt M., Leichte A.B., Fiedler G.-M., Sauter T.C., Fuhrmann V., Exadaktylos A.K. Use of diuretics is not associated with mortality in patients admitted to the emergency department: results from a cross-sectional study. J. of Negative Results in Biomedicine. 2016; 1; 44; doi: 10.1186/s12952-016-0044-1.
- Mann S.J., Ernst M.E. Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention. Current Hypertens. Reports. 2015; 17:30-39.
- Malha L., Mann S.J. Loop diuretics in the treatment of hypertension. Curr. Hypertens. Rep. 2016;18(4):27.
Arquivos suplementares
